

JosÃ© M Carrascosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9223928/publications.pdf>

Version: 2024-02-01

235
papers

5,321
citations

81900

39
h-index

138484

58
g-index

270
all docs

270
docs citations

270
times ranked

4818
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy. Archives of Dermatology, 2012, 148, 463.	1.4	172
2	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€”based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	2.9	136
3	Effect of age and moderate food restriction on insulin sensitivity in Wistar rats: role of adiposity. Journal of Endocrinology, 2007, 194, 131-141.	2.6	114
4	Leptin Impairs Insulin Signaling in Rat Adipocytes. Diabetes, 2004, 53, 347-353.	0.6	107
5	The two isoforms of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. Biochemical and Biophysical Research Communications, 1991, 177, 1013-1018.	2.1	102
6	Long-term food restriction prevents ageing-associated central leptin resistance in wistar rats. Diabetologia, 2002, 45, 997-1003.	6.3	102
7	Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relaciÃ³n entre psoriasis y obesidad e implicaciones terapÃ©uticas. Actas Dermo-sifiligrÃ¡ficas, 2014, 105, 31-44.	0.4	97
8	Documento de consenso sobre la evaluaciÃ³n y el tratamiento de la psoriasis moderada/grave del Grupo EspaÃ±ol de Psoriasis de la Academia EspaÃ±ola de DermatologÃ­a y VenereologÃ­a. Actas Dermo-sifiligrÃ¡ficas, 2009, 100, 277-286.	0.4	95
9	Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. Journal of Investigative Dermatology, 2017, 137, 313-321.	0.7	94
10	Prevalencia de la psoriasis en EspaÃ±a en la era de los agentes biolÃ³gicos. Actas Dermo-sifiligrÃ¡ficas, 2014, 105, 504-509.	0.4	89
11	Ageing increases SOCS-3 expression in rat hypothalamus: effects of food restriction. Biochemical and Biophysical Research Communications, 2002, 296, 425-428.	2.1	87
12	Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. British Journal of Dermatology, 2013, 168, 609-616.	1.5	85
13	Decreased leptin uptake in hypothalamic nuclei with ageing in Wistar rats. Journal of Endocrinology, 2001, 171, 23-32.	2.6	79
14	Directrices espaÃ±olas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biolÃ³gicos. Actas Dermo-sifiligrÃ¡ficas, 2009, 100, 386-413.	0.4	73
15	Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Research, 1984, 44, 3831-5.	0.9	73
16	<i>In Vivo</i> Insulin-Dependent Glucose Uptake of Specific Tissues Is Decreased during Aging of Mature Wistar Rats. Endocrinology, 1997, 138, 49-54.	2.8	66
17	Metotrexato: guÃ­a de uso en psoriasis. Actas Dermo-sifiligrÃ¡ficas, 2010, 101, 600-613.	0.4	65
18	Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Archives of Dermatological Research, 2013, 305, 105-112.	1.9	65

#	ARTICLE	IF	CITATIONS
19	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	6.7	65
20	Body mass index in patients with moderate to severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 907-914.	2.4	62
21	Position statement for the management of comorbidities in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2058-2073.	2.4	61
22	Papular-Purpuric Gloves-and-Socks Syndrome Related to Cytomegalovirus Infection. <i>Dermatology</i> , 1995, 191, 269-270.	2.1	59
23	Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1424-1430.	2.4	57
24	Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 156-163.	2.4	57
25	Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. <i>Journal of Dermatological Treatment</i> , 2019, 30, 424-429.	2.2	57
26	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1695-1706.	2.4	57
27	Sequential Combined Therapy with Thiazidomide and Narrow-Band (TL01) UVB in the Treatment of Prurigo nodularis. <i>Dermatology</i> , 1997, 195, 359-361.	2.1	55
28	Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: modulation by aging and differentiation in rat adipose tissue. <i>Journal of Molecular Endocrinology</i> , 2005, 34, 153-161.	2.5	52
29	Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national <scp>BIOBADADERM</scp> registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 858-864.	2.4	47
30	Impaired Central Insulin Response in Aged Wistar Rats: Role of Adiposity. <i>Endocrinology</i> , 2007, 148, 5238-5247.	2.8	45
31	Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2012, 166, 1237-1244.	1.5	45
32	Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. <i>Dermatology and Therapy</i> , 2018, 8, 173-194.	3.0	45
33	Adherencia y satisfacción del paciente y características organolépticas y de uso de los tratamientos tópicos utilizados para la psoriasis: Consenso Delphi del panel de expertos y miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 488-496.	0.4	43
34	Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidylinositol 3-kinase activity in adipocytes from young and old rats. <i>FEBS Letters</i> , 1998, 425, 298-304.	2.8	39
35	A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 060703142021003-???	2.4	39
36	Changes in the neuroendocrine control of energy homeostasis by adiposity signals during aging. <i>Experimental Gerontology</i> , 2009, 44, 20-25.	2.8	39

#	ARTICLE	IF	CITATIONS
37	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346.	2.2	39
38	The Role of FcÎ³ Receptor Polymorphisms in the Response to Anti-Tumor Necrosis Factor Therapy in Psoriasis. <i>JAMA Dermatology</i> , 2013, 149, 1033.	4.1	38
39	Age-associated development of inflammation in Wistar rats: Effects of caloric restriction. <i>Archives of Physiology and Biochemistry</i> , 2011, 117, 140-150.	2.1	37
40	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
41	Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 128-134.	0.4	37
42	Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 194-206.	0.4	37
43	Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 139-150.	1.2	37
44	Psoriasis e hÃgado graso no alcohÃlico. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 506-514.	0.4	34
45	Reacciones paradÃjicas de los tratamientos biolÃgicos utilizados en psoriasis: revisiÃn de la literatura. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 791-800.	0.4	34
46	Patch testing in children with hand eczema. A 5-year multicentre study in Spain. <i>Contact Dermatitis</i> , 2011, 65, 213-219.	1.4	33
47	Inmunogenicidad en terapia biolÃgica. Implicaciones en DermatologÃa. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 471-479.	0.4	33
48	An Mr 180000 protein is an endogenous substrate for the insulin-receptor-associated tyrosine kinase in human placenta. <i>Biochemical Journal</i> , 1987, 243, 797-801.	3.7	32
49	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 694-709.	0.4	32
50	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. <i>Dermatology and Therapy</i> , 2017, 7, 265-279.	3.0	31
51	Insulin receptor kinase activity in rat adipocytes is decreased during aging. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 303-309.	2.1	30
52	A new era in the management of psoriasis? The biologics: facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 81-87.	1.6	30
53	Prevalence of Psoriasis in Spain in the Age of Biologics. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 504-509.	0.4	30
54	Manifestaciones cutÃneas en el contexto de la infecciÃn por SARS-CoV-2 (COVID-19). <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 734-742.	0.4	30

#	ARTICLE	IF	CITATIONS
55	Papular acrodermatitis of childhood related to poxvirus and parvovirus B19 infection. <i>Cutis</i> , 1998, 61, 265-7.	0.3	30
56	The effect of aging on insulin signalling pathway is tissue dependent: Central role of adipose tissue in the insulin resistance of aging. <i>Mechanisms of Ageing and Development</i> , 2009, 130, 189-197.	4.6	29
57	Lipopolysaccharide-binding protein is increased in patients with psoriasis with metabolic syndrome, and correlates with C-reactive protein. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 81-84.	1.3	29
58	Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. <i>Journal of Dermatological Treatment</i> , 2015, 26, 502-506.	2.2	29
59	Guidelines for the Use of Acitretin in Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2013, 104, 598-616.	0.4	28
60	Isolation and biological characterization of a 6-kDa protein from hepatopancreas of lobster <i>Panulirus argus</i> with insulin-like effects. <i>General and Comparative Endocrinology</i> , 2003, 131, 284-290.	1.8	27
61	Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. <i>Journal of Dermatological Treatment</i> , 2019, 30, 461-465.	2.2	27
62	Revisión actualizada del tratamiento tópico de la psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 190-200.	0.4	26
63	Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 513-517.	1.2	26
64	Dideoxyinosine-Associated Ofuji Papuloerythroderma in an HIV-Infected Patient. <i>Dermatology</i> , 1997, 195, 410-411.	2.1	25
65	Activation of MAP kinase by insulin and vanadate in adipocytes from young and old rats. <i>Molecular and Cellular Endocrinology</i> , 2002, 189, 77-84.	3.2	25
66	Development of Insulin Resistance During Aging: Involvement of Central Processes and Role of Adipokines. <i>Current Protein and Peptide Science</i> , 2011, 12, 305-315.	1.4	25
67	CCL4L Polymorphisms and CCL4/CCL4L Serum Levels Are Associated with Psoriasis Severity. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1830-1837.	0.7	25
68	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
69	Elaboración mediante el método Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo) de la artritis psoriásica. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 216-232.	0.4	24
70	Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2821-2829.	2.4	24
71	Changes in the Kinase Activity of the Insulin Receptor Account for an Increased Insulin Sensitivity of Mammary Gland in Late Pregnancy. <i>Endocrinology</i> , 1998, 139, 520-526.	2.8	22
72	Narrow-band ultraviolet B in aquagenic pruritus. <i>British Journal of Dermatology</i> , 2005, 153, 1233-1234.	1.5	22

#	ARTICLE	IF	CITATIONS
73	Effects of narrowband UV-B on pharmacodynamic markers of response to therapy: an immunohistochemical study over sequential samples. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 769-776.	1.3	22
74	Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. <i>British Journal of Dermatology</i> , 2007, 156, 24-29.	1.5	21
75	Effect of aging on the kinetic characteristics of the insulin receptor autophosphorylation in rat adipocytes. <i>Archives of Biochemistry and Biophysics</i> , 1992, 296, 231-238.	3.0	20
76	The expression of rat resistin isoforms is differentially regulated in visceral adipose tissues: effects of aging and food restriction. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 204-211.	3.4	20
77	Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. <i>Clinical Rheumatology</i> , 2017, 36, 439-443.	2.2	20
78	Letter: A Tattoo Reaction in a Sentinel Lymph Node from a Patient with Melanoma. <i>Dermatologic Surgery</i> , 2007, 33, 766-767.	0.8	19
79	Adherence and Patient Satisfaction With Topical Treatment in Psoriasis, and the Use, and Organoleptic Properties of Such Treatments: A Delphi Study With an Expert Panel and Members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2013, 104, 488-496.	0.4	19
80	Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1700-1708.	2.4	19
81	Treatment of Inverse Psoriasis with Excimer Therapy and Tacrolimus Ointment. <i>Dermatologic Surgery</i> , 2007, 33, 361-363.	0.8	18
82	Realidades y retos de la fotoprotecciÃ³n en la infancia. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2014, 105, 253-262.	0.4	18
83	Activation of phosphatidylinositol-3-kinase by insulin is mediated by both A and B human insulin receptor types. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 123-127.	2.1	17
84	An immunohistopathologic study in cutaneous necrotizing vasculitis. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 130-135.	1.3	17
85	Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 828-829.	2.4	17
86	Lupus erythematosus tumidus: a clinical and histological study of 25 cases. <i>Lupus</i> , 2015, 24, 751-755.	1.6	17
87	Psoriasis and Nonalcoholic Fatty Liver Disease. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2017, 108, 506-514.	0.4	17
88	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. <i>Cellular and Molecular Immunology</i> , 2018, 15, 898-906.	10.5	17
89	Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. <i>Dermatologic Therapy</i> , 2022, 35, e15231.	1.7	17
90	Tyrosine kinase activity of liver insulin receptor is inhibited in rats at term gestation. <i>Biochemical Journal</i> , 1989, 263, 267-272.	3.7	16

#	ARTICLE	IF	CITATIONS
91	Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis. <i>Journal of Infection</i> , 2014, 69, 600-606.	3.3	16
92	Pityriasis rubra pilaris-like reaction induced by imatinib. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 520-522.	1.3	15
93	Supervivencia en terapia biolÃ³gica. Â¿Sabemos a quÃ© nos referimos? Â¿Podemos usarla?. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2014, 105, 729-733.	0.4	15
94	Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. <i>Journal of Dermatological Treatment</i> , 2016, 27, 203-209.	2.2	15
95	Immune-mediated inflammatory diseases differently affect IGRAsâ€™ accuracy for latent tuberculosis infection diagnosis in clinical practice. <i>PLoS ONE</i> , 2017, 12, e0189202.	2.5	15
96	Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. <i>BioDrugs</i> , 2018, 32, 281-291.	4.6	15
97	Caloric restriction attenuates aging-induced cardiac insulin resistance in male Wistar rats through activation of PI3K/Akt pathway. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 97-105.	2.6	15
98	Time to relapse after tildrakizumab withdrawal in patients with moderate to severe psoriasis who were responders at week 28: <i>post hoc</i> analysis through 64 weeks from reSURFACE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 919-927.	2.4	15
99	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.	2.2	15
100	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2009, 100, 386-413.	0.4	14
101	Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2014, 105, 216-232.	0.4	14
102	Women with moderate to severe psoriasis in Spain (<i>BIOBADADERM</i> registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. <i>British Journal of Dermatology</i> , 2019, 181, 1085-1087.	1.5	14
103	Cutaneous Manifestations in the Context of SARS-CoV-2 Infection (COVID-19). <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2020, 111, 734-742.	0.4	14
104	Aging in Male Wistar Rats Associates With Changes in Intestinal Microbiota, Gut Structure, and Cholecystokinin-Mediated Gut-Brain Axis Function. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1915-1921.	3.6	14
105	Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1131-1134.	2.4	13
106	Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. <i>British Journal of Dermatology</i> , 2017, 176, 797-799.	1.5	13
107	A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?. <i>Life</i> , 2021, 11, 627.	2.4	13
108	Acute dermal abscesses caused by <i>Serratia marcescens</i> . <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 891-893.	1.2	12

#	ARTICLE	IF	CITATIONS
109	Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales (II). Actas Dermo-sifiliográficas, 2016, 107, 712-729.	0.4	12
110	Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Actas Dermo-sifiliográficas, 2018, 109, 791-800.	0.4	12
111	Biosimilar and interchangeable: Inseparable scientific concepts?. British Journal of Clinical Pharmacology, 2019, 85, 2460-2463.	2.4	12
112	Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks. Journal of Dermatological Treatment, 2019, 30, 35-39.	2.2	12
113	EFFECTS OF CHRONIC ACARBOSE TREATMENT ON ADIPOCYTE INSULIN RESPONSIVENESS, SERUM LEVELS OF LEPTIN AND ADIPONECTIN AND HYPOTHALAMIC NPY EXPRESSION IN OBESE DIABETIC WISTAR RATS. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 256-261.	1.9	11
114	Effectiveness and Safety of Psoralen-UVA (PUVA) Topical Therapy in Palmoplantar Psoriasis: A Report on 48 Patients. Actas Dermo-sifiliográficas, 2013, 104, 418-425.	0.4	11
115	Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. Journal of Dermatological Treatment, 2018, 29, 140-144.	2.2	11
116	Study of insulin vascular sensitivity in aortic rings and endothelial cells from aged rats subjected to caloric restriction: Role of perivascular adipose tissue. Experimental Gerontology, 2018, 109, 126-136.	2.8	11
117	Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. Journal of Dermatological Treatment, 2020, 31, 344-351.	2.2	11
118	Definition of minimal disease activity in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 422-430.	2.4	11
119	The Role of Photoprotection in Optimizing the Treatment of Atopic Dermatitis. Dermatology and Therapy, 2021, 11, 315-325.	3.0	11
120	Baricitinib for the treatment of atopic dermatitis. Journal of Dermatological Treatment, 2022, 33, 2404-2413.	2.2	11
121	Osteoporosis y psoriasis. Actas Dermo-sifiliográficas, 2019, 110, 642-652.	0.4	11
122	Guidelines on the Use of Methotrexate in Psoriasis. Actas Dermo-sifiliográficas, 2010, 101, 600-613.	0.4	10
123	Sun Protection in Children: Realities and Challenges. Actas Dermo-sifiliográficas, 2014, 105, 253-262.	0.4	10
124	Implicaciones clínicas, diagnósticas y terapéuticas de la psoriasis y enfermedad cardiovascular. Actas Dermo-sifiliográficas, 2017, 108, 800-808.	0.4	10
125	New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Review of Clinical Immunology, 2018, 14, 259-273.	3.0	10
126	Comorbilidades en dermatitis atópica: actualización y controversias. Actas Dermo-sifiliográficas, 2020, 111, 481-486.	0.4	10

#	ARTICLE	IF	CITATIONS
127	Evidence that (a) serine specific protein kinase(s) different from protein kinase C is responsible for the insulin-stimulated actin phosphorylation by placental membrane. FEBS Letters, 1986, 201, 81-86.	2.8	9
128	Altered subcellular distribution of IRS-1 and IRS-3 is associated with defective Akt activation and GLUT4 translocation in insulin-resistant old rat adipocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 197-206.	4.1	9
129	Impairment of skeletal muscle insulin action with aging in Wistar rats: Role of leptin and caloric restriction. Mechanisms of Ageing and Development, 2012, 133, 306-316.	4.6	9
130	Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 292-309.	0.4	9
131	Tollâ€like receptor 9 promoter polymorphism as a predictive factor of narrowâ€band <scp>UVB</scp> phototherapy response in patients with psoriasis. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 98-103.	1.5	9
132	Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 638-643.	0.4	9
133	Phototoxic reaction to a combined oral contraceptive (levonorgestrel/ethinylestradiol). Photochemical and Photobiological Sciences, 2017, 16, 1381-1383.	2.9	9
134	Recomendaciones del Grupo de Psoriasis de la AEDV sobre el manejo de la consulta de psoriasis durante la pandemia por COVID-19. Actas Dermo-sifiliogrÃ¡ficas, 2020, 111, 802-804.	0.4	9
135	Comentarios a las directrices europeas y britÃ¡nicas sobre el tratamiento de la psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2010, 101, 285-290.	0.4	8
136	Enfermedad renal y psoriasis. Â¿Una nueva comorbilidad?. Actas Dermo-sifiliogrÃ¡ficas, 2016, 107, 823-829.	0.4	8
137	Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations. Actas Dermo-sifiliogrÃ¡ficas, 2016, 107, 194-206.	0.4	8
138	Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1021-1028.	2.4	8
139	Expert consensus on the persistence of biological treatments in moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1214-1223.	2.4	8
140	Actinic lichen planus triggered by drug photosensitivity. Photodermatology Photoimmunology and Photomedicine, 2019, 35, 124-126.	1.5	8
141	Effectiveness and safety of ustekinumab 90â€mg in patients weighing 100â€kg or less: a retrospective, observational, multicenter study. Journal of Dermatological Treatment, 2020, 31, 222-226.	2.2	8
142	Biosimilares en el tratamiento de la psoriasis. ActualizaciÃ³n. Actas Dermo-sifiliogrÃ¡ficas, 2020, 111, 809-814.	0.4	8
143	<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>. Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 495-498.	1.8	8
144	Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. Journal of Dermatological Treatment, 2020, 32, 1-8.	2.2	8

#	ARTICLE	IF	CITATIONS
145	Estudio Delphi para el uso de apremilast en la psoriasis. Actas Dermo-sifiliográficas, 2020, 111, 115-134.	0.4	8
146	Basal Cell Carcinoma. Cancer Treatment and Research, 2009, 146, 263-278.	0.5	8
147	Generalized cutaneous drug eruption due to strontium ranelate. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 321-322.	2.4	7
148	Increase in minimal erythematol dose following oral administration of an antioxidant complex based on a mix of carotenoids: Double-blind, placebo-controlled trial. Photodermatology Photoimmunology and Photomedicine, 2017, 33, 284-286.	1.5	7
149	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. Expert Review of Clinical Immunology, 2021, 17, 1-11.	3.0	7
150	Apremilast for psoriasis treatment. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 421-433.	0.8	7
151	Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians. Journal of Dermatological Treatment, 2017, 28, 188-199.	2.2	6
152	Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. Journal of Dermatological Treatment, 2018, 29, 806-811.	2.2	6
153	Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. Journal of the American Academy of Dermatology, 2018, 78, 798-800.	1.2	6
154	Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm. Actas Dermo-sifiliográficas, 2020, 111, 752-760.	0.4	6
155	Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e65-e67.	2.4	6
156	Bacillary angiomatosis presenting as a malleolar ulcer. Archives of Dermatology, 1995, 131, 963-964.	1.4	6
157	Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry. British Journal of Dermatology, 2022, 187, 817-820.	1.5	6
158	Estrategias terapéuticas en el prurigo nodular. Piel, 2001, 16, 360-364.	0.0	5
159	Efectos adversos de la fototerapia: clínica y manejo. Piel, 2008, 23, 447-452.	0.0	5
160	Update of the Topical Treatment of Psoriasis. Actas Dermo-sifiliográficas, 2009, 100, 190-200.	0.4	5
161	Effects of age and caloric restriction on the cardiac and coronary response to endothelin-1 in rats. Experimental Gerontology, 2014, 60, 183-189.	2.8	5
162	Kidney Disease and Psoriasis. A New Comorbidity?. Actas Dermo-sifiliográficas, 2016, 107, 823-829.	0.4	5

#	ARTICLE	IF	CITATIONS
163	Fiabilidad de una aplicación de ayuda a la toma de decisiones terapéuticas en el paciente con psoriasis (MDi Psoriasis [®]). <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 650-656.	0.4	5
164	Informes de posicionamiento terapéutico: utilidad y transparencia. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 3-6.	0.4	5
165	Impairment of the liver insulin receptor autoactivation cascade at full-term pregnancy in the rat. <i>Biochemical Journal</i> , 1995, 311, 523-529.	3.7	4
166	P-37: Role of the C-terminal domain of insulin receptor β^2 -subunit in aging: effects of truncation. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1996, 104, 101-102.	1.2	4
167	BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 132-141.	0.4	4
168	Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 175-186.	0.4	4
169	Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. <i>European Journal of Dermatology</i> , 2014, 24, 662-669.	0.6	4
170	Hidradenitis supurativa: nuevas oportunidades para una enfermedad dermatológica huérfana. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 448-451.	0.4	4
171	Psoriasis y comorbilidad psiquiátrica: la próxima frontera. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 502-505.	0.4	4
172	The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 738-741.	1.2	4
173	The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2110-2117.	2.2	4
174	Aportaciones de un comité multidisciplinar para la prevención de infecciones en pacientes tratados con inmunosupresores selectivos. <i>Medicina Clínica</i> , 2021, 157, 489-494.	0.6	4
175	Adhesion Molecules Associated with Female Genital Tract Infection. <i>PLoS ONE</i> , 2016, 11, e0156605.	2.5	4
176	Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. <i>Annals of Medicine</i> , 2021, 53, 1727-1736.	3.8	4
177	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiliográficas</i> , 2022, 113, T261-T277.	0.4	4
178	Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00678.	1.3	4
179	Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. <i>Dermatology</i> , 2022, 238, 620-629.	2.1	4
180	Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2878-2880.	2.2	4

#	ARTICLE	IF	CITATIONS
181	Regulation of cyclic AMP synthesis and degradation is modified in rat liver at late gestation. <i>Biochemical Journal</i> , 1992, 286, 419-424.	3.7	3
182	A black tongue in a young woman. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 429-430.	1.3	3
183	Fixed sunlight eruption: a new idiopathic photodermatosis rather than a variant of fixed drug eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2017, 33, 222-224.	1.5	3
184	Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 52-58.	0.4	3
185	Osteoporosis and Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2019, 110, 642-652.	0.4	3
186	The Use of Apremilast in Psoriasis: A Delphi Study. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 115-134.	0.4	3
187	Ichthyosiform eruption and facial erythema secondary to ponatinib therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 743-747.	0.8	3
188	Pemetrexed-induced oedema of the eyelids and scalp in a patient with metastatic lung cancer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e322-e324.	2.4	3
189	Fototerapia en el prurigo nodular. Experiencia propia y revisión de la literatura. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 339-344.	0.4	3
190	Prevalence and stages of chronic kidney disease in psoriasis and psoriatic arthritis: A cross-sectional study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 321-321.	0.6	3
191	Phototherapy for Prurigo Nodularis: Our Experience and a Review of the Literature. <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 339-344.	0.4	3
192	Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 941-953.	1.4	3
193	Allergic contact dermatitis to 2(thiocyano-methylthio) benzothiazole present in a packaging wood. <i>Contact Dermatitis</i> , 2007, 57, 121-122.	1.4	2
194	El futuro se hace presente en fotoprotección solar. <i>Piel</i> , 2011, 26, 311-314.	0.0	2
195	Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it?. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 729-733.	0.4	2
196	Expert Recommendations on Treating Psoriasis in Special Circumstances (Part II). <i>Actas Dermo-sifiliográficas</i> , 2016, 107, 712-729.	0.4	2
197	Reliability of the MDi Psoriasis Application to Aid Therapeutic Decision-Making in Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 650-656.	0.4	2
198	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e709-e711.	2.4	2

#	ARTICLE	IF	CITATIONS
199	Disseminated StrongyloidesÂstercoralis infection withÂaÂcutaneous presentation inÂanÂimmunosuppressed patient. European Journal of Dermatology, 2009, 19, 404-405.	0.6	2
200	Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors. Dermatology and Therapy, 2021, 11, 2027-2042.	3.0	2
201	[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. Actas Dermo-sifiliogrÃ¡ficas, 2022, 113, T401-T406.	0.4	2
202	Vegetative lesions associated with inhaled cocaine use. Clinical and Experimental Dermatology, 2022, 47, 1586-1588.	1.3	2
203	Short-term effect of glutamine on the incorporation of glucose-carbon into nucleic acids in Ehrlich ascites tumour cells. Biochimie, 1990, 72, 291-293.	2.6	1
204	Characteristics of Patients With Hand Dermatitis Referred to the Contact Dermatitis Unit of a Tertiary Hospital and Impact of Patch Testing on Diagnosis. Actas Dermo-sifiliogrÃ¡ficas, 2009, 100, 493-498.	0.4	1
205	Expert Recommendations on Treating Psoriasis in Special Circumstances. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 292-309.	0.4	1
206	Photoinduced targetâ€like drug reaction to naproxen. Photodermatology Photoimmunology and Photomedicine, 2016, 32, 323-326.	1.5	1
207	Clinical, Diagnostic, and Therapeutic Implications in Psoriasis Associated With Cardiovascular Disease. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 800-808.	0.4	1
208	Patch Testing During the COVID-19 Pandemic: Recommendations of the AEDV's Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC). Actas Dermo-sifiliogrÃ¡ficas, 2020, 111, 650-654.	0.4	1
209	Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. Actas Dermo-sifiliogrÃ¡ficas, 2020, 111, 752-760.	0.4	1
210	Psoriasis moderada-grave en pacientes pediÃ¡tricos y jÃ³venes: experiencia en el registro BIOBADADERM. Actas Dermo-sifiliogrÃ¡ficas, 2022, 113, 401-406.	0.4	1
211	Knowledge, perceptions, attitude, barriers and facilitators of biosimilars use across specialty physicians and hospital pharmacists: A national survey. Farmacia Hospitalaria, 2021, 45, 240-246.	0.6	1
212	PÃºrpura. FMC Formacion Medica Continuada En Atencion Primaria, 2001, 8, 215-229.	0.0	0
213	Consensus Document on Therapy With Bath Psoralen-UV-A. Actas Dermo-sifiliogrÃ¡ficas, 2007, 98, 164-170.	0.4	0
214	Should Minor and Benign Cutaneous Lesions Be Treated by the Health Service?. Actas Dermo-sifiliogrÃ¡ficas, 2007, 98, 236-239.	0.4	0
215	Reply to: â€œTreatment of Minor and Benign Skin Lesions in the Spanish Public Health System: Experience in Health Area 19 of the Autonomous Community of Valenciaâ€: Actas Dermo-sifiliogrÃ¡ficas, 2008, 99, 234-235.	0.4	0
216	RÃ©plica: Â«PatologÃa cutÃ¡nea benigna banal y sistema pÃºblico. Experiencia en el Departamento de Salud 19 de la Comunidad ValencianaÂ». Actas Dermo-sifiliogrÃ¡ficas, 2008, 99, 234-235.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Narrowband Ultraviolet B Therapy in Psoriasis: Reality, Outlook, and Uncertainty. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 3-6.	0.4	0
218	Commentary on European and British Guidelines for the Treatment of Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 285-290.	0.4	0
219	Leukemia Cutis Arising at the Site of Injection of a Tetanus Vaccine Booster. <i>Actas Dermo-sifiliográficas</i> , 2010, 101, 727-729.	0.4	0
220	Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study. <i>Actas Dermo-sifiliográficas</i> , 2011, 102, 354-364.	0.4	0
221	Mecanismo de acción de ustekinumab y su relevancia en la patogénesis de la psoriasis. Impacto en el sistema inmune. <i>Actas Dermo-sifiliográficas</i> , 2012, 103, 7-15.	0.4	0
222	<i>Actas Dermo-Sifiliográficas</i> , bilingüe en Pubmed. <i>Actas Dermo-sifiliográficas</i> , 2013, 104, 95.	0.4	0
223	IL-17 in psoriasis. The final frontier or just another brick in the wall?. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 6-8.	0.4	0
224	Therapeutic implications of IL-17A blockade in psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 1-5.	0.4	0
225	Hidradenitis Suppurativa: New Opportunities for an Orphan Skin Disease. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 448-451.	0.4	0
226	Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 638-643.	0.4	0
227	Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 52-58.	0.4	0
228	New treatments in psoriasis. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 157-159.	0.2	0
229	Nuevos tratamientos en psoriasis. <i>Medicina Clínica</i> , 2017, 149, 157-159.	0.6	0
230	Psoriasis and Psychiatric Disorders: The Next Frontier. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 502-505.	0.4	0
231	Biosimilars in the Treatment of Psoriasis: An Update. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 809-814.	0.4	0
232	Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, .	2.4	0
233	Cutis Marmorata Telangiectatica Congenita or Neonatal Lupus?. <i>Pediatrics International</i> , 1996, 13, 230-232.	0.5	0
234	Contributions from a multidisciplinary committee for the prevention of infections in patients with targeted immunosuppressive therapy. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 489-489.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Development of morphea during Nivolumab treatment. Australasian Journal of Dermatology, 2022, , .	0.7	0